文献速递呼吸衰竭与机械通气心脑血管急症

直接口服抗凝药时代低危肺栓塞的门诊治疗:一项系统评价

Outpatient Treatment of Low-risk Pulmonary Embolism in the Era of Direct Oral Anticoagulants: A Systematic Review.
PubMed 文献 · Acad Emerg Med · 2020-09-20
一句话结论低危肺栓塞门诊治疗患者90天内主要不良结局(全因死亡、肺栓塞相关死亡、复发性静脉血栓栓塞、大出血)均低于1%。

该系统评价检索了1980年1月至2019年2月的多个数据库,纳入12项研究(4项随机对照试验、8项非随机试验),共3191例成人急性症状性肺栓塞患者,均在急诊科或48小时内出院。门诊治疗患者(n=1814)90天全因死亡率为0.7%(95%CI 0.4%-1.2%),肺栓塞相关死亡率为0.06%(95%CI 0.01%-0.3%),复发性静脉血栓栓塞为0.8%(95%CI 0.5%-1.4%),大出血为0.8%(95%CI 0.5%-1.4%)。探索性分析未发现抗凝药物类别与主要不良结局发生率之间存在关联。

要点

  • 低危肺栓塞门诊治疗患者90天全因死亡率为0.7%(95%CI 0.4%-1.2%),肺栓塞相关死亡率为0.06%(95%CI 0.01%-0.3%)。
  • 门诊治疗患者90天复发性静脉血栓栓塞发生率为0.8%(95%CI 0.5%-1.4%),大出血发生率为0.8%(95%CI 0.5%-1.4%)。
  • 探索性分析未发现抗凝药物类别与主要不良结局发生率之间存在关联。
  • 纳入的12项研究中,4项随机对照试验和6项非随机试验为低至中等偏倚风险,被归类为高质量研究。

适用人群与场景

  • 成人急性症状性肺栓塞患者,从急诊科出院或48小时内出院。
  • 纳入英语随机对照试验和前瞻性非随机试验。

研究设计与关键结果

  • 系统评价纳入12项研究(4项随机对照试验、8项非随机试验),共3191例患者。
  • 门诊治疗患者(n=1814)90天主要不良结局:全因死亡率0.7%(95%CI 0.4%-1.2%),肺栓塞相关死亡率0.06%(95%CI 0.01%-0.3%),复发性静脉血栓栓塞0.8%(95%CI 0.5%-1.4%),大出血0.8%(95%CI 0.5%-1.4%)。
  • 探索性分析未发现抗凝药物类别与主要不良结局发生率之间存在关联。

证据类型、等级与局限

  • 证据类型:系统评价,纳入4项随机对照试验和8项前瞻性非随机试验。
  • 所有随机对照试验和6项非随机试验为低至中等偏倚风险,被归类为高质量研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于低危肺栓塞患者,门诊治疗与90天内主要不良结局(全因死亡、肺栓塞相关死亡、复发性静脉血栓栓塞、大出血)发生率低于1%相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Clinical guidelines have supported outpatient treatment of low-risk pulmonary embolism (PE) since 2014, but adoption of this practice has been slow. Direct oral anticoagulant (DOAC) therapy for venous thromboembolism (VTE) is now as common as vitamin K antagonist treatment, but data are sparse regarding outcomes for patients with low-risk PE treated with DOACs as outpatients. We conducted a systematic review of literature on outcomes of outpatient management for PE, including comparisons to inpatient treatment and differences by anticoagulant class.

METHODS: We searched Medline, Embase, PubMed, CENTRAL, clinicaltrials.gov, and ICTRN for studies published from January 1980 through February 2019 using a predefined strategy developed with a medical librarian. We included English-language randomized controlled trials (RCTs) and prospective nonrandomized trials (NRTs) of adult patients diagnosed with acute, symptomatic PE, and discharged from the emergency department or within 48 hours. Our primary outcome included four major adverse outcomes (all-cause mortality, PE-related mortality, recurrent VTE, and major bleeding) within 30 and 90 days. A preplanned subanalysis of high-quality studies assessed outcomes associated with different anticoagulation treatment classes.

RESULTS: Our initial search identified 6,818 records, of which 12 studies (four RCT, eight NRT) with a total of 3,191 patients were included in the review. All RCTs and six NRTs were determined to have low to moderate risk of bias and were classified as high quality. Outpatients in these studies (n = 1,814) had rates of 90-day major adverse outcomes below 1%, including all-cause mortality (0.7%, 95% confidence interval [CI] = 0.4% to 1.2%), PE-related mortality (0.06%, 95% CI = 0.01% to 0.3%), recurrent VTE (0.8%, 95% CI = 0.5% to 1.4%), and major bleeding (0.8%, 95% CI = 0.5% to 1.4%). Exploratory analysis revealed no association between anticoagulant treatment class and rates of major adverse outcomes.

CONCLUSION: Among patients with low-risk PE treated as outpatients, few patients experienced major adverse outcomes such as mortality, recurrent VTE, or major bleeding within 90 days.

来源:Acad Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Maughan BC, Frueh L, McDonagh MS, et al. Outpatient Treatment of Low-risk Pulmonary Embolism in the Era of Direct Oral Anticoagulants: A Systematic Review. Acad Emerg Med. 2020. PMID: 32779290. doi:10.1111/acem.14108

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。